New Stock News | It is reported that mRNA pharmaceutical company DeepTrust Biotechnology plans to go public in Hong Kong, aiming to raise approximately 200 million USD
According to reports, mRNA drug developer DeepTrust Bio plans to go public in Hong Kong. It is in discussions with CICC and Jefferies for a potential IPO, which could happen as early as next year, raising approximately $200 million. The report cites sources stating that details such as the scale and timing of the IPO are still in preliminary discussions and may change. Public information shows that DeepTrust Bio was established in 2019 and is one of the few companies globally that master the core technology of LNP underlying design. It has established an mRNA-LNP technology platform with independent intellectual property rights and has built a library of over 5,000 ionizable lipid resources for screening LNP carriers suitable for different therapeutic scenarios. The company has multiple internal R&D pipelines in the fields of infectious disease vaccines, rare diseases, and tumor immunotherapy. According to Qichacha data, DeepTrust Bio has undergone several rounds of financing, with investors including CR HOLDINGS, DCM, CPE Yuanfeng, Qianhai Fangyuan Capital, E Fund, Blue Ocean Capital, Zhongke Chuangxing, Qianhai Mother Fund, Dongping Balance Capital, Junlian Capital, Zhifei Biological, and Lanting Capital
According to reports, mRNA drug developer DeepTrust Bio plans to go public in Hong Kong. It is in discussions with CICC and Jefferies for a potential IPO, which could happen as early as next year, raising approximately $200 million. The report cites sources stating that details such as the scale and timing of the IPO are still in preliminary discussions and may change.
Public information shows that DeepTrust Bio was established in 2019 and is one of the few companies globally that master the core technology of LNP underlying design. It has established an mRNA-LNP technology platform with independent intellectual property rights globally, building a library of over 5,000 ionizable lipid resources for screening LNP carriers suitable for different therapeutic scenarios. The company has laid out multiple internal R&D pipelines in the fields of infectious disease vaccines, rare diseases, and tumor immunology.
According to Qichacha data, DeepTrust Bio has undergone several rounds of financing, with investors including CR HOLDINGS, DCM, CPE Yuanfeng, Qianhai Fangyuan Capital, E Fund, Blue Ocean Capital, Zhongke Chuangxing, Qianhai Mother Fund, Dongping Balance Capital, Junlian Capital, Zhifei Biological, and Lanting Capital
